PurposeThe purpose of this study was to evaluate the effect of consolidation immunotherapy on patients with stage III non-small cell lung cancer (NSCLC) who received induction chemoimmunotherapy before chemoradiotherapy (CRT).Materials and methodsPatients with stage III NSCLC who received induction chemoimmunotherapy before CRT with or without consolidation immunotherapy at 4 hospitals between February 2018 and December 2022 were retrospectively analyzed. The patients were divided into two groups on the basis of whether they received consolidation immunotherapy (Ind+Con group) or not (Ind group).
Progression-free survival (PFS) and overall survival (OS) were assessed from the initiation of treatment and were estimated using the Kaplan–Meier method. One-to-one propensity score matching (PSM) was used to further minimize confounding effects.ResultsA total of 196 eligible patients were enrolled, with 124 (63.3%) in the Ind group and 72 (36.7%) in the Ind+Con group.
The median follow-up was 24.6 months, and the median PFS and OS for the whole cohort were 24.8 months and 46.0 months, respectively. The median PFS was 25.5 months in the Ind group vs.
Frontiers in Immunology published a clinical update in Infectious Disease on 28 Apr 2026.
The item focuses on The effect of consolidation immunotherapy on patients with stage III non-small cell lung cancer who received induction chemoimmunotherapy: a multicenter retrospective study.
Review the original article for the full source wording and details.